Sélim Corm

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini et al. · New England Journal of Medicine · 2010 · 386 citations

Pharmacy, Hematology, Pharmacotherapy +6

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Andreas Hochhaus, Michele Baccarani, Michael W. Deininger et al. · Leukemia · 2008 · 354 citations

Medicine, Hematology, Oncology +13

Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study

Cécile Pautas, Fatiha Merabet, Xavier Thomas et al. · Journal of Clinical Oncology · 2010 · 217 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)

Franck E. Nicolini, Sélim Corm, Q.H. Le et al. · Leukemia · 2006 · 203 citations

Life Sciences, Genetics, Hematology +15

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

Jörge E. Cortes, D-W Kim, Emmanuel Raffoux et al. · Leukemia · 2008 · 201 citations

Medicine, Pharmacology, Pharmacotherapy +8